Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, Chen J, Chung D, Harju-Baker S, Özpolat T, Fink KR, Riddell SR, Maloney DG, Turtle CJ.

Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.

PMID:
29025771
2.

Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation.

Bhattacharyya A, Hanafi LA, Sheih A, Golob JL, Srinivasan S, Boeckh MJ, Pergam SA, Mahmood S, Baker KK, Gooley TA, Milano F, Fredricks DN, Riddell SR, Turtle CJ.

Biol Blood Marrow Transplant. 2018 Feb;24(2):242-251. doi: 10.1016/j.bbmt.2017.10.003. Epub 2017 Oct 9.

PMID:
29024803
3.

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.

PMID:
28924019
4.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG.

J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.

PMID:
28715249
5.

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.

Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, Prunkard D, Colunga AG, Hanafi LA, Clegg DO, Turtle C, Russell DW.

Nat Biotechnol. 2017 Aug;35(8):765-772. doi: 10.1038/nbt.3860. Epub 2017 May 15.

6.

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG.

Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.

7.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

8.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.

9.

Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.

Hanafi LA, Gauchat D, Godin-Ethier J, Possamaï D, Duvignaud JB, Leclerc D, Grandvaux N, Lapointe R.

PLoS One. 2014 Jun 9;9(6):e99211. doi: 10.1371/journal.pone.0099211. eCollection 2014.

10.

A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells.

Pallet N, Sirois I, Bell C, Hanafi LA, Hamelin K, Dieudé M, Rondeau C, Thibault P, Desjardins M, Hebert MJ.

Proteomics. 2013 Apr;13(7):1108-20. doi: 10.1002/pmic.201200531.

PMID:
23436686
11.

[Acute postinfectious glomerulonephritis].

Ramdani B, Zamd M, Hachim K, Soulami K, Ezzahidy M, Souiri M, Fadili W, Lahboub A, Hanafi L, Boujida M, Squalli S, Benkirane A, Benghanem MG, Medkouri G.

Nephrol Ther. 2012 Jul;8(4):247-58. doi: 10.1016/j.nephro.2011.11.011. Epub 2012 Apr 6. Review. French.

PMID:
22483748
12.

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.

Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R.

Clin Cancer Res. 2011 Nov 15;17(22):6985-91. doi: 10.1158/1078-0432.CCR-11-1331. Epub 2011 Nov 8. Review.

13.

IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive.

Godin-Ethier J, Hanafi LA, Duvignaud JB, Leclerc D, Lapointe R.

Mol Immunol. 2011 Oct;49(1-2):253-9. doi: 10.1016/j.molimm.2011.08.017. Epub 2011 Sep 19.

PMID:
21937116
14.

Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes.

Hanafi LA, Bolduc M, Gagné ME, Dufour F, Langelier Y, Boulassel MR, Routy JP, Leclerc D, Lapointe R.

Vaccine. 2010 Aug 2;28(34):5617-26. doi: 10.1016/j.vaccine.2010.06.024. Epub 2010 Jun 25.

PMID:
20600515
15.

Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance.

Godin-Ethier J, Pelletier S, Hanafi LA, Gannon PO, Forget MA, Routy JP, Boulassel MR, Krzemien U, Tanguay S, Lattouf JB, Arbour N, Lapointe R.

J Immunol. 2009 Dec 15;183(12):7752-60. doi: 10.4049/jimmunol.0901004.

Supplemental Content

Loading ...
Support Center